Print this page    •   Back to Web version of article

U.S. News
Gilead HIV Drug as Effective as Merck's in Trial

March 25, 2011

Gilead Sciences Inc. this week reported late-stage clinical trial results showing that its experimental once-daily HIV drug elvitegravir proved as effective as Merck & Co.'s twice-daily drug Isentress (raltegravir). In the study, patients were given an antiretroviral regimen plus elvitegravir or Isentress. After 48 weeks, 59 percent of the elvitegravir patients had achieved the targeted viral load levels, versus 57.8 percent of the Isentress group. Discontinuation rates due to adverse events were comparable in both groups. Gilead plans to submit the presentation data later this year at a scientific conference. Elvitegravir is designed to thwart HIV's ability to invade human cells' genetic material.

Back to other news for March 2011

Excerpted from:
Reuters
03.23.2011; Toni Clark




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art61198.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.